Glenmark sold its API arm and halved R&D to pivot into branded drugs (interview)
Chairman Glenn Saldanha tells the Economic Times how divesting Glenmark Life Sciences paid down debt and reset the company on branded products.
What was changed
In an interview with The Economic Times published November 19, 2024, Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said the Indian drugmaker was repositioning itself as a branded pharmaceutical company, chasing higher margins in respiratory, dermatology and oncology after 'three, four difficult years' of problems with the US FDA, the Department of Justice and litigation. 'All that is behind us,' he said. 'The platform is set to continue to scale and to grow faster.'
The pivot rested on portfolio rationalisation: Glenmark sold Glenmark Life Sciences, its active pharmaceutical ingredient business, reasoning that changing generics dynamics made the API business unnecessary. Saldanha said the sale helped 're-channelise our entire energies into becoming a branded company', and the proceeds went to paying down debt. He also addressed analyst doubts about the sale and about some branded portfolios being divested: 'We will not give up (on) scale.'
The company's numbers reflected the reset: a debt-to-equity ratio of just 0.16%, R&D spend halved from a peak of $120–130 million a year to about $60 million through a series of out-licensing deals, and expected revenues of Rs 13,500–14,000 crore for the year, with growth of about 12–15% CAGR and roughly Rs 15,500 crore targeted the following year.
Why it worked
Years of FDA, DOJ and litigation trouble had weighed on the generics-led model and pushed the company to rethink where its returns came from.
Branded products carry higher margins than the API and generics businesses, so the divestment funded a move up the value chain.
The API sale proceeds retired debt, cutting the debt-to-equity ratio to 0.16% and freeing the balance sheet for the new strategy.
Out-licensing deals let Glenmark halve R&D spending to about $60 million while keeping a pipeline, replacing internal spend with partner economics.
What can be applied
Selling a business you built is easier to justify when it funds the pivot: divesting the API unit cleared debt and concentrated the company on the branded products it actually wants to compete in.
Aftermath
As of the November 2024 interview, Glenmark guided to Rs 13,500–14,000 crore of revenue for the year, about 12–15% growth, and roughly Rs 15,500 crore the next year, with Saldanha insisting the company's 'aggression and passion' were intact. The GLS divestment had left the company nearly debt-free at 0.16% debt-to-equity, and the halved R&D budget was being sustained by successive out-licensing deals rather than internal discovery spend.